Product logins

Find logins to all Clarivate products below.


Osteoarthritic Pain | Treatment Algorithms | Claims Data Analysis | US | 2024

In the United States, osteoarthritic pain affects about 32 million people; an aging population and the increasing prevalence of obesity are predicted to fuel additional growth. Several treatment classes may be prescribed to reduce the pain and/or increase patients’ mobility, such as intra-articular agents, antidepressants, NSAIDs, and antiepileptic drugs (AEDs). However, widely applicable and well-tolerated alternatives are needed. In this crowded and largely generic market, a detailed understanding of treatment patterns is essential for the successful introduction of a novel analgesic.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed osteoarthritic pain? What are the quarterly trends in prescribing among recently treated and newly diagnosed osteoarthritic pain patients?
  • How has Pacira’s Zilretta been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of osteoarthritic pain patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of osteoarthritic pain patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: Pacira Biosciences, Collegium Pharmaceuticals, Protega Pharmaceuticals, Averitas Pharma, Kowa

Key drugs: Zilretta, injectable corticosteroids, hyaluronic acid preparations, NSAIDs, antidepressants, AEDs (e.g., gabapentin), opioids (e.g., Xtampza ER), Qutenza

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Myelofibrosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Myelofibrosis is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Symptoms include severe anemia, weakness, fatigue, and splenomegaly. The only…
Report
Bispecific Therapies – Access & Reimbursement – Access & Reimbursement – Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma and Multiple Myeloma (US)
Bispecific therapies provide a valuable treatment option in hematological cancers, offering an “off-the-shelf” option for oncologists to treat patients with B-cell Non-Hodgkin’s lymphoma or…
Report
Alopecia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss. The immune system mistakenly targets anagen hair follicles. While topical…
Report
Chronic Kidney Disease – Unmet Need – Unmet Need – Chronic Kidney Disease (US/EU)
Chronic kidney disease (CKD) encompasses a set of heterogeneous disorders that gradually damage the kidney’s structure or function. The CKD treatment landscape continues to evolve as the adoption…